QBW276 1500mcg ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 299 | Cystic fibrosis | 2 |
299. Cystic fibrosis
Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-004915-35-DE (EUCTR) | 26/07/2017 | 14/10/2015 | Safety and effect of QBW276 in patients with cystic fibrosis | A randomized, double blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of inhaled QBW276 in patients with cystic fibrosis - Safety,pharmacokinetics and pharmacodynamics study of inhaledQBW276 in patients with cystic fibrosis | Cystic Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: QBW276 300mcg Product Code: QBW276 INN or Proposed INN: Not established Other descriptive name: QBW276 Succinate Product Name: QBW276 1500mcg Product Code: QBW276 INN or Proposed INN: Not established Other descriptive name: QBW276 Succinate | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 56 | Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;Germany;United Kingdom | ||
| 2 | EUCTR2014-004915-35-GB (EUCTR) | 02/12/2015 | 16/10/2015 | Safety and effect of QBW276 in patients with cystic fibrosis | A randomized, double blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of inhaled QBW276 in patients with cystic fibrosis - Safety,pharmacokinetics and pharmacodynamics study of inhaledQBW276 in patients with cystic fibrosis | Cystic Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: QBW276 300mcg Product Code: QBW276 INN or Proposed INN: Not established Other descriptive name: QBW276 Succinate Product Name: QBW276 1500mcg Product Code: QBW276 INN or Proposed INN: Not established Other descriptive name: QBW276 Succinate | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 56 | Phase 1;Phase 2 | United States;Germany;United Kingdom |